California Retina Consultants | Santa Barbara, CA

Research site

(Unclaimed)

Location

525 E Micheltorena Street, Suite A & D, Santa Barbara, California, United States of America

Site insights

Top conditions

Top treatments

Ranibizumab

Lampalizumab

Bevacizumab

APL-2

-Ranibizumab

Faricimab

Dexamethasone

Pegcetacoplan

Axitinib

Lucentis

Parent organization

This site is a part of California Retina Consultants

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 62 total trials

A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (PAVILION)

Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DM...

Active, not recruiting

Diabetic Retinopathy

Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab

Drug: Intravitreal Ranibizumab 0.5 mg Injection

A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)

The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of OCS 01 as compared to Vehicle...

Active, not recruiting

Diabetic Macular Edema

Drug: Dexamethasone ophthalmic suspension (OCS-01)

Drug: Vehicle

A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Subtudy to Evaluate the Safety of Re-Implanting the PDS With Ranibizumab in Participants With DME (Pagoda)

This study will evaluate the efficacy, safety, and pharmacokinetics of the PDS with Ranibizumab in participants with DME when treated every 24 weeks...

Enrolling

Diabetic Macular Edema

Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab

Drug: Ranibizumab refill exchange

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD (GALE)

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting

Geographic Atrophy Secondary to Age-related Macular Degeneration

Drug: PEGCETACOPLAN (APL-2)

Extension Study for the Port Delivery System With Ranibizumab (Portal)

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with ne...

Enrolling

Neovascular Age-Related Macular Degeneration

Drug: PDS Implant with Ranibizumab 100 mg/mL

Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy

OPL-0401-201 is a multicenter study to investigate the safety and efficacy of OPL-0401 in patients with diabetes mellitus (DM) with diabetic retinopa...

Active, not recruiting

Non-proliferative Diabetic Retinopathy

Proliferative Diabetic Retinopathy

Drug: Placebo

Drug: OPL-0401 Dose 1

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD (ATMOSPHERE)

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular d...

Enrolling

Choroidal Neovascularization

Wet Age-related Macular Degeneration

Genetic: ABBV-RGX-314

Biological: Ranibizumab (LUCENTIS®)

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME) (ALTITUDE®)

ABBV-RGX-314 is being developed as a novel, potential one-time gene therapy treatment for the treatment of Diabetic Retinopathy (DR) with and without...

Enrolling

Diabetic Retinopathy (DR)

Center-Involved Diabetic Macular Edema (CI-DME)

Genetic: ABBV-RGX-314 Dose 4

Biological: Aflibercept